Status:
COMPLETED
WB-DWI for Early Prediction of Therapy Response in Patients With Advanced Metastatic GIST Treated With Regorafenib
Lead Sponsor:
Universitaire Ziekenhuizen KU Leuven
Conditions:
Gastrointestinal Stromal Tumors
Eligibility:
All Genders
Brief Summary
The purpose of this study is to evaluate WB DWI as early predictor of response to treatment with regorafenib or placebo in patients with advanced metastatic GIST.
Detailed Description
Aim of the study \- To assess whole body diffusion-weighted magnetic resonance imaging (WB-DWI) for the assessment and early prediction of response of treatment with regorafenib or placebo in patient...
Eligibility Criteria
Inclusion
- patients with advanced, metastatic gastro-intestinal stromal tumors treated with regorafenib or placebo
Exclusion
- in case of a known contraindication for MRI (eg. pacemaker), the patient will not be admitted to the study
Key Trial Info
Start Date :
January 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT01265979
Start Date
January 1 2011
End Date
September 1 2011
Last Update
April 10 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radiology Department
Leuven, Leuven, Belgium, 3000